

Randomized, double-blind, placebo controlled trial.
Patients with CD in clinical, biochemical and endoscopic remission on IFX for at least a year were randomly assigned to:
Continue IFX or placebo for 48 weeks.

Primary endpoint:
Time to relapse.

Results:

- No relapses in the group of patients who continued IFX.
- In those on placebo 23/56 (41.1%) relapsed.
- Relapse free survival at 48w was 100% for IFX vs 51% for placebo

Conclusions:

Discontinuation of infliximab for patients with Crohn's disease receiving long-term infliximab therapy and in clinical, biochemical, and endoscopic remission leads to a considerable risk of relapse.

Discontinuation of Infliximab Therapy in Patients with Crohn's Disease

